Abstract:The deposition of β-amyloid (Aβ) in the brain is a biomarker of Alzheimer’s disease (AD). Highly sensitive Aβ positron emission tomography (PET) imaging plays an essential role in diagnosing and evaluating the therapeutic effects of AD. To synthesize a new Aβ tracer [18F]DRKXH1 (5-(4-(6-(2-[18]fluoroethoxy)ethoxy)imidazo[1,2-alpha]pyridin-2-yl)phenyl) and evaluate the tracer performance by biodistribution analysis, in vivo small-animal PET-CT dynamic scan, ex vivo and in vitro autoradiography, and PET in human subjects. [18F]DRKXH1 was synthesized automatically by the GE FN module. Log D (pH 7.4) and biodistribution of [18F]DRKXH1 were investigated. Small-animal-PET was used for [18F]DRKXH1 and [18F]AV45 imaging study in AD transgenic mice (APPswe/PSEN1dE9) and age-matched normal mice. The distribution volume ratios (DVR) and standardized uptake value ratios (SUVRs) were calculated with the cerebellum as the reference region. The deposition of Aβ plaques in the brain of AD transgenic mice was determined by ex vivo autoradiography and immunohistochemistry. In vitro autoradiography was performed in the postmortem brain sections of AD patients and healthy controls. Two healthy control subjects and one AD patient was subjected to in vivo PET study using [18F]DRKXH1. The yield of [18F]DRKXH1 was 40%, and the specific activity was 156.64 ± 11.55 GBq/μmol. [18F]DRKXH1 was mainly excreted through the liver and kidney. The small-animal PET study showed high initial brain uptake and rapid washout of [18F]DRKXH1. The concentration of [18F]DRKXH1 was detected in the cortex and hippocampus of AD transgenic mice brain. The cortex DVR of AD transgenic mice was higher than that of WT mice (P < 0.0001). Moreover, the SUVRs of AD transgenic mice were higher than those of WT mice based on the 0–60-min dynamic scanning. In vitro autoradiography showed a significant concentration of tracer in the Aβ plaque-rich areas in the brain of AD transgenic mice. The DVR value of [18F]-DRKXH1 is higher than that of [18F]-AV45 (1.29 ± 0.05 vs. 1.05 ± 0.08; t = 5.33, P = 0.0003). Autoradiography of postmortem human brain sections showed [18F]DRKXH1-labeled Aβ plaques in the AD brain. The AD patients had high retention in cortical regions, while healthy control subjects had uniformly low radioactivity uptake. [18F]DRKXH1 is an Aβ tracer with high sensitivity in preclinical study and has the potential for in vivo detection of the human brain.

Evaluation in Postmortem Human Alzheimer's Disease Brain Hippocampus and PET/CT Imaging in 5xFAD Transgenic Mice

In vivo Imaging With 18F-FDG- and 18F-Florbetaben-PET/MRI Detects Pathological Changes in the Brain of the Commonly Used 5XFAD Mouse Model of Alzheimer's Disease

Evaluation of a novel PET tracer [18F]-Florbetazine for Alzheimer's disease diagnosis and β-amyloid deposition quantification

International consensus on the use of tau PET imaging agent 18 F-flortaucipir in Alzheimer’s disease

Evaluation of a Novel PET Tracer [18F]-Florbetazine for Alzheimer's Disease Diagnosis and (3-Amyloid Deposition Quantification

Screening of [18f]florbetazine for Aβ Plaques and a Head-to-Head Comparison Study with [11c]pittsburgh Compound-B ([11c]pib) in Human Subjects

[18F]fluoroazabenzoxazoles As Potential Amyloid Plaque PET Tracers: Synthesis and in Vivo Evaluation in Rhesus Monkey.

PET Imaging of Translocator Protein (18 Kda) in a Mouse Model of Alzheimer's Disease Using N-(2,5-Dimethoxybenzyl)-2-18F-Fluoro-N-(2-Phenoxyphenyl)Acetamide

Design, Synthesis, and Preliminary Evaluation of [18F]-Aryl Flurosulfates PET Radiotracers Via SuFEx Methods for Β-Amyloid Plaques in Alzheimer’s Disease

Novel 18F-Labeled Benzofuran Derivatives with Improved Properties for Positron Emission Tomography (PET) Imaging of Β-Amyloid Plaques in Alzheimer’s Brains

Study Of Tau Deposition In Patients Of Alzheimer'S Disease With [F-18]-Apn-1607 Pet Tracer And Its Relationship With Cerebral Glucose Metabolism

Novel 18F-Labeled Benzoxazole Derivatives As Potential Positron Emission Tomography Probes for Imaging of Cerebral Β-Amyloid Plaques in Alzheimer’s Disease

Preclinical and Clinical Study on [18F]DRKXH1: a Novel Β-Amyloid PET Tracer for Alzheimer’s Disease

Associations of [18F]-APN-1607 Tau PET Binding in the Brain of Alzheimer’s Disease Patients With Cognition and Glucose Metabolism

[F-18]D3FSP ([F-18]D3AV-45) as a PET imaging agent for Abeta plaques in the brain

Novel Β-Amyloid PET Imaging Study of [18F]92 in Patients with Cognitive Decline

The Alzheimer's disease 5xFAD mouse model is best suited to investigate pretargeted imaging approaches beyond the blood-brain barrier

Clinical evaluation of [18F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer's disease

Fluorine-18-Labeled Diaryl-azines As Improved Β-Amyloid Imaging Tracers: from Bench to First-in-Human Studies

Improved Automated Synthesis Of [F-18]Finh-Me Via Direct Radio-Fluorination And Quality Control For A Beta-Amyloid Imaging

β-amyloid plaque deposition in the brain of Alzheimer′s disease mouse model by 18F-FINH-Me imaging